Phase III trial in 314 patients with essential hypertension: low-dose telmisartan/amlodipine/chlorthalidone single pill lowered sitting systolic BP more than telmisartan 40 mg at 8 weeks (difference -4.0 mm Hg), with comparable adverse events.
RCTn = 314
Ahn et al. Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT